Tenders Are Invited For Pharmaceutical Products - Completion Of Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V For The Active Ingredient Evolocumab - Vv83

Pharmaceutical Products - Completion Of Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V For The Active Ingredient Evolocumab - Vv83. The Gwq Serviceplus Ag Intends That Non-Exclusive Discount Agreements According To Section 130A (8) Sgb V To The Above. To Close The Active Ingredient With The Start Of The Contract On April 1St, 2025. All Interested Companies Can Join This Contract At Any Time Of The Contract Period On The Same Conditions (Registration Model). The Gwq Assumes That This Procedure Does Not Fall Into The Scope Of The Antitrust Godlife Law Due To A Lack Of Selection Decision And Therefore The Possibility Of Discriminatory Access Of All Pharmaceutical Companies. The Contract Documents, The Participating Health Insurance Companies And Their Sales As Well As The Dates For The Reporting Of The Contract Must Be Viewed And Downloaded On The Award Portal Of Gwq Serviceplus Ag At Http://Vergestportal.Gwq-Serviceplus.De. Until The Start Of Exclusive Contracts, This Transitional Agreement Is Open To All Market Participants To Join. If The Signed Contracts / Explanation And Evidence On 10.03.2024, An Initial Report On April 1, 2025 Can Be Realized. The Following Documents Must Be Submitted: - Unsigned Contract In Double Copy; - List Of The Pzn (Appendix 2) In Question; - Proof Of The Drug Law Approval By Means Of An Extract From The Public Part Of The Amicdatenbank; - Signed Self -Declaration (Appendix 3); - Self -Declaration On The Eu Ordinance (Appendix 5) - Self -Disclosure For Sustainability (Appendix 6)